Rapid Micro Biosystems, Inc.
NASDAQ:RPIDMedical - Devices
+$0.03 today
- Market cap
- $50.31M
- Beta
- 1.46
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$1.10
Volume 0.17M
Average 0.18M
RPID Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Rapid Micro Biosystems, Inc.NASDAQ: RPID
Operating Margin · Q1 FY2026 · quarter ended Mar 2026
Operating margin narrows to -173.1%
Operating margin was -173.1% in Q1 FY2026, down 11.3 pp from a year earlier. On a trailing-twelve-month basis it was -144.2%, up 15.4 pp year over year. Over 3 fiscal years it widened by 227.9 pp.
Context
- Operating margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether operating margin reaches the consensus estimate from 3 analysts of -105.7% for the fiscal year ending Dec 2026, up from -141.1% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -173.1%-64.9 pp QoQ
- Last fiscal yearDec 2025
- -141.1%+36.9 pp YoY
- LTMMar 2026
- -144.2%+15.4 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -11.3 pp | +30.2 pp | +41.5 pp |
| 1 year | +36.9 pp | +35.4 pp | -1.5 pp |
| 3 years | +227.9 pp | +112.7 pp | -115.2 pp |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -141.1%
- Year-over-year change
- +36.9pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -141.1% | +36.9pp |
| FY2024 | 2024-12-31 | -178.0% | +73.2pp |
| FY2023 | 2023-12-31 | -251.2% | +117.8pp |
| FY2022 | 2022-12-31 | -369.0% | -165.7pp |
| FY2021 | 2021-12-31 | -203.3% | — |
Operating Margin vs competitors
How RPID compares with its peers on the latest reported figures
- RPID's LTM Mar 2026 operating margin of -144.2% is the 5th highest of the 7 companies compared; the peer median is -41.6%.
- Its year-over-year change of +15.4 pp is the 4th highest of 7, against a peer median of +13.4 pp.
- Over three fiscal years its change of +227.9 pp compares with a peer median of +31.0 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -7.7% | +24.6 pp | +40.7 pp | |
| LTM Mar 2026 | -10.3% | +9.9 pp | +114.5 pp | |
| LTM Mar 2026 | -28.7% | -11.8 pp | +15.0 pp | |
| LTM Mar 2026 | -54.6% | +16.9 pp | +21.3 pp | |
| LTM Mar 2026 | -144.2% | +15.4 pp | +227.9 pp | |
| LTM Mar 2026 | -959.6% | +184.6 pp | +13844.6 pp | |
| LTM Mar 2026 | -64235.1% | -32245.5 pp | -28032.3 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding RPID) | -41.6% | +13.4 pp | +31.0 pp | |
Competitors are the stored peer set for RPID. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 23.23M | 17.13M | 22.52M | 28.05M | 33.59M |
| Cost of Revenue | 30.97M | 25.67M | 28M | 28.16M | 25.98M |
| Gross Profit | (7.74M) | (8.54M) | (5.49M) | (109K) | 7.61M |
| Gross Margin | -33.3% | -49.8% | -24.4% | -0.4% | 22.7% |
| Research & Development | 9.78M | 12.87M | 12.82M | 14.6M | 13.6M |
| Selling, General & Admin | 29.71M | 41.81M | 38.26M | 35.21M | 34.84M |
| Operating Expenses | 39.49M | 54.68M | 51.08M | 49.81M | 55M |
| Depreciation & Amortization | 1.53M | 2.84M | 3.11M | 3.36M | 3.25M |
| EBITDA | (69.25M) | (58.55M) | (49.33M) | (43.51M) | (42.74M) |
| EBITDA Margin | -298.1% | -341.7% | -219.1% | -155.1% | -127.3% |
| Operating Income | (47.23M) | (63.22M) | (56.56M) | (49.92M) | (47.39M) |
| Operating Margin | -203.3% | -369.0% | -251.2% | -178.0% | -141.1% |
| Interest Income | 0 | 1.78M | 4.21M | 3.16M | 1.51M |
| Interest Expense | 2.65M | 0 | 0 | 0 | 1.09M |
| Other Income / Expenses | (26.2M) | 1.84M | 4.13M | 3.05M | 309K |
| Income Before Tax | (73.43M) | (61.38M) | (52.44M) | (46.87M) | (47.08M) |
| Pre-Tax Margin | -316.1% | -358.3% | -232.9% | -167.1% | -140.2% |
| Income Tax Expense | 91K | (576K) | 31K | 22K | 40K |
| Net Income | (73.52M) | (60.81M) | (52.47M) | (46.89M) | (47.12M) |
| Net Margin | -316.5% | -354.9% | -233.0% | -167.2% | -140.3% |
| EPS (Basic) | (1.88) | (1.43) | (1.22) | (1.08) | (1.05) |
| EPS (Diluted) | (1.88) | (1.43) | (1.22) | (1.08) | (1.05) |
| Weighted Avg Shares | 41.47M | 42.45M | 43.02M | 43.58M | 44.68M |
| Weighted Avg Shares (Diluted) | 41.47M | 42.45M | 43.02M | 43.58M | 44.68M |
Rapid Micro Biosystems, Inc.
NASDAQ:RPID
Intrinsic Alpha fair value
Locked
Current Price
$1.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.